There are 2789 resources available
105P - Prognostic value of the NTRK fusion biomarker in the Netherlands
Presenter: Irene Santi
Session: ePoster Display
148P - Phase III study of everolimus or placebo in addition to adjuvant hormone therapy for high risk early breast cancer: Subgroup analysis of the UCBG UNIRAD trial
Presenter: Paul Cottu
Session: ePoster Display
212P - HER2-low breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment
Presenter: Federica Miglietta
Session: ePoster Display
74P - A predictive signature for response to immunotherapy in non-small cell lung cancer based on plasma proteomics and clinical parameters
Presenter: Yuval Shaked
Session: ePoster Display
154P - Five-year follow-up of the phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in patients with HER2 positive early or locally advanced breast cancer
Presenter: Xavier Pivot
Session: ePoster Display
76P - Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial
Presenter: Ana Oaknin
Session: ePoster Display
77P - Identification of prognostic and predictive immunological biomarkers in stage I and III non-small cell lung cancer (NSCLC) patients: A prospective exploratory study
Presenter: Rianne Vaes
Session: ePoster Display
78P - Prognostic value of thyroid transcription factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1
Presenter: Loïck Galland
Session: ePoster Display
159P - SiMosein, a real-life prospective evaluation of EndoPredict use in early ER-positive, HER2-negative breast cancers
Presenter: Jacqueline Lehmann-Che
Session: ePoster Display